Assessment of quality of life in tuberculosis patients at Aland Taluk in Kalaburagi district

Vanishree P. Babladi; Sachin Patil; Mukteshwarachary Kondaparthi; Pooja V. Salimath; Syed A. U. Biyabani; Bhagyashree S. Nandyal

doi:10.18203/2349-3933.ijam20260389

Authors

Vanishree P. Babladi Department of Pharmacy Practice, Matoshree Taradevi Institute of Pharmaceutical Sciences, Kalaburagi, Karnataka, India
Sachin Patil Department of Pharmacy Practice, Matoshree Taradevi Institute of Pharmaceutical Sciences, Kalaburagi, Karnataka, India
Mukteshwarachary Kondaparthi Department of Pharmacy Practice, Matoshree Taradevi Institute of Pharmaceutical Sciences, Kalaburagi, Karnataka, India
Pooja V. Salimath Department of Pharmacy Practice, Matoshree Taradevi Institute of Pharmaceutical Sciences, Kalaburagi, Karnataka, India
Syed A. U. Biyabani Department of Pharmacy Practice, Matoshree Taradevi Institute of Pharmaceutical Sciences, Kalaburagi, Karnataka, India
Bhagyashree S. Nandyal Department of Pharmacy Practice, Matoshree Taradevi Institute of Pharmaceutical Sciences, Kalaburagi, Karnataka, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20260389

Keywords:

Tuberculosis, Health-related quality of life, Pharmacist counselling, Patient education, Outcome enhancement

Abstract

Background: Tuberculosis (TB), a recalcitrant infectious disorder precipitated by Mycobacterium tuberculosis, continues to pose a formidable public health burden, exerting pervasive and long-standing detriments to health-related quality of life (HRQOL). Despite sustained implementation of national control initiatives such as the directly observed treatment, short-course (DOTS) program, TB prevalence in India remains disproportionately elevated, particularly within rural and socioeconomically marginalized populations. The disease’s multisystemic impact necessitates comprehensive evaluation beyond microbiological and clinical indices. The objective of the study was to critically appraise the quality of life among individuals diagnosed with TB in the Aland region of Kalaburagi district and to ascertain the contributory impact of structured pharmacist-led counselling on patient outcomes.

Methods: A six-month prospective observational study was conducted across selected areas of Aland Taluk. Of 416 enrolled participants, 409 completed the study. Individuals aged 16–80 years were randomly assigned to intervention and control cohorts. Baseline sociodemographic characteristics and HRQOL parameters were assessed using standardized WHOQOL instruments, with follow-up evaluation performed at three months. Data were subjected to appropriate inferential statistical analysis.

Results: Baseline assessment revealed a predominance of active TB cases in both cohorts. Post-intervention analysis demonstrated a substantial reduction in disease burden in the intervention group (29.61%) compared with the control group (10.34%). Significant improvements were observed across all HRQOL domains, with consistently superior outcomes in the pharmacist-intervention cohort.

Conclusions: Pharmacist-mediated counselling significantly enhanced HRQOL and attenuated TB-related burden, underscoring its strategic value within integrated tuberculosis management frameworks.

Metrics

Metrics Loading ...

References

World Health Organization. Tuberculosis. WHO Definition and Overview. Geneva: WHO. 2015. Available at: https://www.who.int/health-topics /tuberculosis#tab=tab_1. Accessed on 06 October 2025.

Centres for Disease Control and Prevention. Transmission and Pathogenesis of Tuberculosis. Atlanta: CDC. 2016. Available at: https://stacks.cdc. gov/view/cdc/80807/. Accessed on 06 October 2025.

World Health Organization. Global Tuberculosis Report 2014. Geneva: WHO. 2014. Available at: https://www.who.int/publications/i/item/9789241564809. Accessed on 06 October 2025.

World Health Organization. Global tuberculosis report 2016. Geneva: WHO. 2016. Available at: https://www.who.int/publications/i/item/9789241565394. Accessed on 06 October 2025.

World Health Organization. Latent tuberculosis infection: Updated and consolidated guidelines. Geneva: WHO. 2018. Available at: https://www.who .int/publications/i/item/9789241550239. Accessed on 06 October 2025.

Lawn SD, Zumla AI. Tuberculosis. Lancet. 2011;378(9785):57-72. DOI: https://doi.org/10.1016/S0140-6736(10)62173-3

Comstock GW. Epidemiology of tuberculosis. Am Rev Respir Dis. 1982;125(3):8-15.

World Health Organization. Global Tuberculosis Report 2015. Geneva: WHO. 2015. Available at: https://www.who.int/publications/i/item/9789241565059. Accessed on 06 October 2025.

United Nations Children's Fund. Tuberculosis: Women and Children Statistics. New York: UNICEF. 2016. Available at: https://data.unicef.org /resources/state-worlds-children-2016-statistical-tables/. Accessed on 06 October 2025.

Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection–associated tuberculosis: the epidemiology and response. Clin Infect Dis. 2010;50(S3):S201-7. DOI: https://doi.org/10.1086/651492

Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new End TB Strategy. Lancet. 2015;385(9979):1799-801. DOI: https://doi.org/10.1016/S0140-6736(15)60570-0

World Health Organization. TB mortality and global burden statistics 2015. Geneva: WHO. 2015. Available at: https://iris.who.int/bitstream/handle /10665/191102/9789241565059_eng.pdf. Accessed on 06 October 2025.

World Health Organization. Global Tuberculosis Report 2017. Geneva: WHO. 2017. Available at: https://www.who.int/publications/i/item/9789241565516. Accessed on 06 October 2025.

Revised National Tuberculosis Control Programme (RNTCP). TB India Report 2017. New Delhi: Ministry of Health & Family Welfare, Government of India. 2017. Available at: https://tbcindia.mohfw. gov.in/wp-content/uploads/2023/05/4773363959 TOG-Chapter-1-Introduction.pdf. Accessed on 06 October 2025.

Central TB Division. Programmatic Management of Drug-Resistant TB Guidelines. New Delhi: MoHFW. 2016. Available at: https://tbcindia.mohfw.gov.in/wp -content/uploads/2025/01/National-Guidelines-for-Management-of-DR-TB_Final.pdf. Accessed on 06 October 2025.

Government of India. Universal Drug Susceptibility Testing under RNTCP. New Delhi: MoHFW. 2017. Available at: https://tbcindia.mohfw.gov.in/wp-content/uploads/2023/05/8368587497Guidelines-for-PMDT-in-India-1.pdf. Accessed on 06 October 2025.

Chauhan LS, Rao SV. Tuberculosis control in India. J Indian Med Assoc. 2002;100(5):296-300.

Bauer M, Leavens A, Schwartzman K. A systematic review of psychosocial issues in tuberculosis. Int J Tuberc Lung Dis. 2013;17(4):479-89. DOI: https://doi.org/10.5588/ijtld.13.0496

Brown J, Capocci S, Smith C, Morris S, Abubakar I. Health-related quality of life in TB patients. Thorax. 2015;70(4):416-21.

Marra CA, Marra F, Cox VC, Palepu A, Fitzgerald JM. Health-related QoL in TB. Chest. 2004;125(2):389-97. DOI: https://doi.org/10.1186/1477-7525-2-58

Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. ATS/CDC/IDSA Clinical Practice Guidelines for TB Treatment. Clin Infect Dis. 2016;63(7):e147-95.

World Health Organization. The Stop TB Strategy and DOTS Implementation. Geneva: WHO. 2010. Available at: https://www.ncbi.nlm.nih.gov/books /NBK310770/, Accessed on 06 October 2025.

Blomberg B, Spinaci S, Fourie B, Laing R. The role of fixed-dose combinations in TB treatment. Int J Tuberc Lung Dis. 2001;5(4):332-43.

Ghimire S, Nepal S, Bhuvan KC. Tuberculosis patient education and counselling: A review. J Clin Tuberc Other Mycobact Dis. 2019;17:100122.

Bond C, Raehl CL. Pharmacist-provided care and outcomes in tuberculosis management. Am J Health Syst Pharm. 2007;64(22):2414-24. DOI: https://doi.org/10.2146/ajhp060631